. The chemist and druggist [electronic resource] . dividual patients or in reaction to their differentresponses to treatment Some argue formulation problems make thepolypill impractical. Another point of view is thatgiving patients lifestyle tablets will discouragethem from adopting healthier habits, such astaking more exercise and improving their diet. Andyet another school of thought says to treat peoplefor risks they dont appear to have is to over-medicalise their condition. All of these points of view have support fromhealth professionals - so exactly how do ProfessorTaylor and other propo
. The chemist and druggist [electronic resource] . dividual patients or in reaction to their differentresponses to treatment Some argue formulation problems make thepolypill impractical. Another point of view is thatgiving patients lifestyle tablets will discouragethem from adopting healthier habits, such astaking more exercise and improving their diet. Andyet another school of thought says to treat peoplefor risks they dont appear to have is to over-medicalise their condition. All of these points of view have support fromhealth professionals - so exactly how do ProfessorTaylor and other proponents defend the polypill7 The proposition that the drug makers havedeliberately floated a seductive idea to makemoney from older treatments doesnt stand up,observes Professor Taylor, not least because itstoo late - the drugs concerned are all off-patent. On the question of flexibility, he argues thatcreating a default position in which over-55s areoffered a polypill would not prevent individualsbeing given specific treatments if they are 4 WE HAVE TO BALANCETHE NEED FORCAUTION AGAINST THESHEER FOLLY OFWAITING TOO LONG[FOR THE POLYPILL] 5 If you say heres the basic offer for the mass ofthe healthy over-55s, its not the same as sayingits one size fits all, he says. If it becomes clear apatient is at special risk and needs a completelydifferent set of treatments, theres no reason whythey should not have it. Whats more, he warns, cardiologists tell methe personalisation of drug treatment too oftenleads to the use of sub-optimal combinations thatare not as rational as fixed dose combinationproducts based on the best available evidence. Professor Taylor agrees there might bedifficulties in creating and establishing polypillsfor vascular disease prevention, but suggests theyshould not be insuperable for a drug industry thatsucceeded in creating practical combinationtreatments for HIV. He also rejects the chargethat creating a lifestyle tablet would be regardedas an alternati
Size: 1363px × 1834px
Photo credit: © Reading Room 2020 / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: ., bookcentury1800, bookdecade185, booksubjectpharmacy, bookyear1859
